AI Article Synopsis
Article Abstract
We report on 11 critically ill burn patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. Clinical success was achieved in 36% and complicated by treatment-emergent resistance and interpatient transmission of cefiderocol-resistant A. baumannii. Resistant isolates harbored disrupted pirA and piuA genes that were not disrupted among susceptible isolates.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169418 | PMC |
| http://dx.doi.org/10.1093/cid/ciac647 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reduce susceptibility to cefiderocol in gram negative bacteria in children: Is hope already lost before it's even arrived?
J Infect Public Health
April 2024
Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Background: In last years the diffusion of carbapenem resistance in Gram-negative bacteria (CR-GNB) is increasing worldwide, mainly due to the expression of carbapenemases. Cefiderocol has molecular characteristics that ideally confers activity against all CR-GNB, but resistant strains have already been identified. We describe cefiderocol susceptibility profile among multi-drug resistant Gram-negative isolated from pediatric patients.
View Article and Find Full Text PDFEvolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit.
Clin Infect Dis
February 2023
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
We report on 11 critically ill burn patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. Clinical success was achieved in 36% and complicated by treatment-emergent resistance and interpatient transmission of cefiderocol-resistant A. baumannii.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!